STAARVISC II

Aid, Surgical, Viscoelastic

FDA Premarket Approval P000046

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for reference rights to p810025, and for staar surgical company to distribute the sodium hyaluronate under the tradename staarvisc(tm) ii. The device is indicated for use during surgery in the anterior and posterior segments of the human eye. Procedures include: cataract extraction, intraocular lens (iol) implantation, corneal transplantation surgery, glaucoma filtering surgery and surgical procedures to reattach the retina. Staarvisc9tm) ii is designed to create and maintain anterior chamber depth and visibility, protect corneal endothelial cells and other intraocular tissues, minimize interation between tissues during surgical manipulation, and act as a vitreous substitute during retinal reattachment surgery. Staarvisc(tm) ii also preserves tissue integrity and good visibility when used to fill the anterior and posterior segments of the eye following open sky procedures.

DeviceSTAARVISC II
Classification NameAid, Surgical, Viscoelastic
Generic NameAid, Surgical, Viscoelastic
ApplicantAnika Therapeutics, Inc.
Date Received2000-11-06
Decision Date2001-04-18
Notice Date2001-05-14
PMAP000046
SupplementS
Product CodeLZP
Docket Number01M-0227
Advisory CommitteeOphthalmic
Expedited ReviewNo
Combination Product No
Applicant Address Anika Therapeutics, Inc. 32 Wiggins Avenue bedford, MA 01730
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P000046Original Filing
S030 2021-11-23 Normal 180 Day Track No User Fee
S029 2021-07-29 Normal 180 Day Track No User Fee
S028 2021-05-04 30-day Notice
S027 2019-05-24 Real-time Process
S026 2017-02-14 Normal 180 Day Track No User Fee
S025 2014-06-10 30-day Notice
S024 2014-06-02 30-day Notice
S023 2014-01-15 Normal 180 Day Track No User Fee
S022 2013-12-27 30-day Notice
S021 2013-12-26 30-day Notice
S020 2011-11-04 30-day Notice
S019 2010-11-01 Normal 180 Day Track No User Fee
S018 2010-11-03 30-day Notice
S017 2010-09-30 Normal 180 Day Track No User Fee
S016 2009-10-02 Normal 180 Day Track No User Fee
S015 2009-05-27 Normal 180 Day Track
S014 2006-07-24 30-day Notice
S013 2006-01-03 30-day Notice
S012 2005-09-07 Special (immediate Track)
S011 2005-07-07 Special (immediate Track)
S010 2004-06-17 30-day Notice
S009 2004-05-07 30-day Notice
S008 2003-04-25 30-day Notice
S007 2002-11-27 Normal 180 Day Track
S006 2002-10-15 Normal 180 Day Track
S005
S004 2002-05-21 Normal 180 Day Track
S003 2002-04-17 Real-time Process
S002 2002-03-18 Normal 180 Day Track
S001 2001-05-10 Real-time Process

NIH GUDID Devices

Device IDPMASupp
00817337000012 P000046 000
00866142000021 P000046 000
00866142000038 P000046 016
00866142000045 P000046 019
30886158020067 P000046 023
00866142000052 P000046 030
00817337000128 P000046 030

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.